AbbVie’s Rinvoq (upadacitinib) Meets its Primary Endpoint in the P-IIb Study for Non-Segmental Vitiligo
Shots:
- The P-IIb study evaluating Rinvoq in adults with NSV. The trial met the 1EPs of percent change from baseline in F-VASI at 24wk. with the 11 & 22mg doses, percent reduction from baseline in F-VASI at 52wk. was numerically greater than the results at 24wk.
- At 24wk., percent CFB in F-VASI at upadacitinib 6, 11 & 22mg doses (-22.0, -35.6 & -34.0 vs -14.4), higher response rates were observed in 2EPs incl. F-VASI 75 (8.2%, 19.1% & 14.0% vs 2.2%) and T-VASI 50 (6.1%, 6.4% & 11.6% vs 2.2%). At 52wk. percent CFB in F-VASI (-52.3, -62.8 & -59.2); F-VASI 75 (28.6%, 51.1% & 25.6%); T-VASI 50 (24.5%, 31.9% & 27.9%), respectively
- No new safety signals were seen, and treatment discontinuation due to TEAEs was observed in the upadacitinib (22mg) over the other groups
Ref: AbbVie | Image: AbbVie
Related News:-
AbbVie Presents P-III (Measure Up 1), (Measure Up 2) and (AD Up) Studies Results of Rinvoq for Atopic Dermatitis at 32nd EADV Congress 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
